176 related articles for article (PubMed ID: 25297769)
1. [Chromosomal abnormalities and clonal evolution in multiple myeloma].
Ishida T
Rinsho Ketsueki; 2014 Oct; 55(10):2036-45. PubMed ID: 25297769
[No Abstract] [Full Text] [Related]
2. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.
Schmidt-Hieber M; Gutiérrez ML; Pérez-Andrés M; Paiva B; Rasillo A; Tabernero MD; Sayagués JM; Lopez A; Bárcena P; Sanchez ML; Gutiérrez NC; San Miguel JF; Orfao A
Haematologica; 2013 Feb; 98(2):279-87. PubMed ID: 22929983
[TBL] [Abstract][Full Text] [Related]
3. Acta Oncologica and a new generation of scientists in oncology.
Glimelius B; Johansen C; Muren LP; Nilbert M
Acta Oncol; 2014 Jul; 53(7):849-51. PubMed ID: 24954366
[No Abstract] [Full Text] [Related]
4. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
[TBL] [Abstract][Full Text] [Related]
5. [Examination of molecular markers used n the treatment of colon cancer].
Domagała P; Kowalik A
Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S59-77. PubMed ID: 26165036
[No Abstract] [Full Text] [Related]
6. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
[TBL] [Abstract][Full Text] [Related]
7. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
Gralewski JH; Post GR; van Rhee F; Yuan Y
Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
[TBL] [Abstract][Full Text] [Related]
8. Activating Ras mutations in patients with plasma-cell disorders: a reappraisal.
Bezieau S; Avet-Loiseau H; Moisan JP; Bataille R
Blood; 2002 Aug; 100(3):1101-2; author reply 1103. PubMed ID: 12150155
[No Abstract] [Full Text] [Related]
9. Molecular genetical examinations of multiple myeloma and other B-cell malignancies.
Kita K; Miwa H; Ohno T; Shirakawa S
Nihon Ketsueki Gakkai Zasshi; 1986 Dec; 49(8):1729-39. PubMed ID: 3105207
[No Abstract] [Full Text] [Related]
10. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
11. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance.
Kim SY; Im K; Park SN; Kim JA; Yoon SS; Lee DS
Leuk Res; 2016 May; 44():45-52. PubMed ID: 27015231
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
13. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
14. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.
Rasmussen T; Kuehl M; Lodahl M; Johnsen HE; Dahl IM
Blood; 2005 Jan; 105(1):317-23. PubMed ID: 15339850
[TBL] [Abstract][Full Text] [Related]
15. Expression profile of telomere-associated genes in multiple myeloma.
Díaz de la Guardia R; Catalina P; Panero J; Elosua C; Pulgarin A; López MB; Ayllón V; Ligero G; Slavutsky I; Leone PE
J Cell Mol Med; 2012 Dec; 16(12):3009-21. PubMed ID: 22947336
[TBL] [Abstract][Full Text] [Related]
16. New Targets and New Agents in High-Risk Multiple Myeloma.
Nooka AK; Lonial S
Am Soc Clin Oncol Educ Book; 2016; 35():e431-41. PubMed ID: 27249751
[TBL] [Abstract][Full Text] [Related]
17. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
Bass A
J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
[No Abstract] [Full Text] [Related]
18. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.
Bohn OL; Hsu K; Hyman DM; Pignataro DS; Giralt S; Teruya-Feldstein J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e65-8. PubMed ID: 24445188
[No Abstract] [Full Text] [Related]
19. [Cytogenetic and molecular basis of multiple myeloma].
Taniwaki M; Matsumoto Y
Nihon Rinsho; 2007 Dec; 65(12):2179-86. PubMed ID: 18069258
[TBL] [Abstract][Full Text] [Related]
20. FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma.
Korać P; Peran I; Skrtić A; Ajduković R; Kristo DR; Dominis M
Pathol Int; 2009 May; 59(5):354-8. PubMed ID: 19432679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]